KLP Kapitalforvaltning’s Vaxcyte PCVX Stock Holding History

KLP Kapitalforvaltning’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.65M	Buy	29,000 +1,300	+5%	+$75.8K	0.01%	847
2026 Q2	$1.61M	Buy	27,700 +1,800	+7%	+$97.8K	0.01%	885
2026 Q1	$1.51M	Buy	25,900 +900	+4%	+$48.9K	0.01%	829
2025 Q4	$1.15M	Buy	25,000 +400	+2%	+$17.9K	﹤0.01%	964
2025 Q3	$886K	Hold	24,600	–	–	﹤0.01%	1100
2025 Q2	$800K	Buy	24,600 +1,600	+7%	+$52.4K	﹤0.01%	1106
2025 Q1	$868K	Buy	23,000 +500	+2%	+$40K	﹤0.01%	1006
2024 Q4	$1.84M	Buy	+22,500	New	+$2.23M	0.01%	693

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

KLP Kapitalforvaltning's PCVX Position: Q3 2026 in Review

KLP Kapitalforvaltning increased its Vaxcyte (PCVX) stake by 4.7% in Q3 2026, buying an estimated $75.8K and bringing the position to 29,000 shares worth $1.65M. The position accounts for 0.01% of the portfolio, ranked #847.

KLP Kapitalforvaltning first reported a position in PCVX in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.84M in Q4 2024. 167 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

KLP Kapitalforvaltning held 29,000 shares of Vaxcyte worth $1.65M as of Q3 2026.
KLP Kapitalforvaltning bought 1,300 Vaxcyte shares in Q3 2026, an estimated $75.8K.
Vaxcyte made up 0.01% of KLP Kapitalforvaltning's portfolio in Q3 2026, its #847 holding.
KLP Kapitalforvaltning first reported a position in Vaxcyte in Q4 2024 and has held it in 8 quarters since.
KLP Kapitalforvaltning's Vaxcyte position peaked at $1.84M in Q4 2024.
167 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q3 2026, filed 10 Nov 2026.